Pinnacle Biologics specializes in revitalizing healthcare therapies by promoting, developing and managing innovative approaches to the global commercialization of products in the oncology and specialty areas.
They accomplish this through licensing and acquisition of specialty pharmaceuticals and medical devices. Their innovative approach to opportunity analysis, business development, lifecycle management, regulatory expertise and distribution leverage takes each product to its highest degree of potential and maximum patient benefit.
Funding Rounds (1) - $1.5MUpdate
Current Team (2)Update
|Jun 1, 2016||PRWeb Sitemap - Regulatory Compliance Associates® Inc. Welcomes Dr. Sharon Ayd as Chief Scientific Officer / Senior Vice President Pharmaceuticals|
|Dec 15, 2015||PRNewswire All - Concordia Healthcare Announces Intent to Repay US$45 Million Debt, and Inclusion to Nasdaq Biotech Index|
|Nov 23, 2015||PRNewswire All - Concordia Healthcare Announces Launch of First Pipeline Product, and Positive Amendment to Earn-out Terms of AMCo Agreement|
|Aug 5, 2015||PRNewswire UK All - Drug Device Combination Products Market Will Report a Market Value Worth US$115 Billion by 2019: Transparency Market Research|
|Sep 12, 2013||SEC - SEC FORM D|
2801 Lakeside Dr
Deerfield, IL 60015